
Introduction Recreational nitrous oxide (N2O) use is a public health concern in the United Kingdom due to neurological complications such as subacute combined degeneration of the spinal cord. When managed through inpatient hospital admission, this places significant strain on inpatient and acute services. In response, an N2O-Same Day Emergency Care (SDEC) pathway was established at Barts Health National Health Service (NHS) Trust to reduce hospital admissions, enable timely treatment and ease pressure on acute services.Methods A retrospective cost analysis was conducted using data from 295 patients treated for N2O-induced myeloneuropathy at Barts Health NHS Trust between 2014 and 2025. The study compared direct healthcare costs across three pathways: (1) standard inpatient care, (2) SDEC with nurse-administered vitamin B12 (non-self-injection pathway (SIP)) and (3) SDEC with SIP. Resource utilisation was mapped using electronic health records and costs via Patient Level Information Costing System and NHS tariff data.Results The average cost per patient was highest for standard inpatient care (£4359.70), compared with non-SIP (£1519.05) and SIP (£1117.59), representing savings of 65.2% and 74.4% respectively (p<0.001). Inpatient admission accounted for nearly half the total cost in standard inpatient care. In unadjusted analyses, diagnostic imaging and neurology clinic follow-up were lower in ambulatory care pathways (p<0.001), although these differences are likely influenced by variation in follow-up duration and non-attendance rate. Readmission within 30 days was not recorded in any group. Inpatient admission was required in 67% of standard pathway patients, compared with lower proportions in the non-SIP (1.3%) and SIP (3%) groups (p<0.001).Conclusions Ambulatory care, particularly SIP, was associated with lower direct healthcare costs for N2O-induced myeloneuropathy, with no 30-day readmissions identified within Barts Health NHS Trust records, although longer term clinical outcomes were not assessed. The findings support consideration of structured ambulatory models, with prospective studies needed to assess long-term outcomes.
Background Traumatic brain injury (TBI) is a risk factor for dementia, but it is unclear whether interventions post TBI reduce risk of subsequent cognitive decline or dementia. Commissioned by the WHO, this review evaluated the effectiveness of post-TBI interventions on cognitive outcomes and dementia risk.Methods We searched MEDLINE, Embase, PsycINFO and Cochrane Library from inception to February 2025. We included studies that evaluated post-TBI interventions and reported cognitive function, mild cognitive impairment (MCI) or dementia outcomes.Results 16 studies met inclusion criteria, of which eight were included in the Grading of Recommendations Assessment, Development and Evaluation (GRADE) synthesis. Two studies reported dementia outcomes and none reported incident MCI. Across all studies, the evidence for reducing dementia risk or improving cognition was of low or very low certainty.Conclusion The available evidence was insufficient to determine whether any specific post-TBI interventions are effective for reducing the risk of cognitive decline or dementia. Substantial gaps remain for long-term outcomes, women and low-income settings.PROSPERO registration number CRD420251027658.
Introduction Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited disease-modifying treatment options. Preclinical and clinical data suggest that cannabinoid-based therapies may exert neuroprotective and symptomatic benefits. We conducted a trial to evaluate the effects of cannabis-based medicine extract (CBME) on disease progression in patients with ALS.Methods This was a randomised, double-blind, placebo-controlled trial. Participants received CBME or placebo for 6 months. The primary outcome was the difference in ALS Functional Rating Scale-Revised (ALSFRS-R) scores at the end of treatment (EOT). Secondary outcomes included adverse events, forced vital capacity (FVC), pain and spasticity measures, weight loss, cognition and quality of life.Results Due to COVID-19 restrictions and driving limitations, only 17 participants were enrolled (CBME: n=8; placebo: n=9), and 8 completed treatment (4 per group). At EOT, adjusted mean ALSFRS-R scores were 31.67 for CBME and 34.33 for placebo (difference: −2.66; 95% CI −7.25 to 1.92; p=0.18; n=8). No significant differences were observed in secondary outcomes. Post hoc analyses suggested potential effects of CBME on pain and cognition for further confirmation: usual pain intensity decreased by 2.52 points (95% CI −8.92 to 3.87, p=0.34; n=8), a decrease of 3 days in the number of pain days (95% CI −28.90 to 22.59, p=0.75; n=8), executive function improved by 7.71 points (95% CI 0.90 to 14.52; p=0.04; n=8) and a 5.68-point improvement in memory (95% CI −0.29 to 11.64; p=0.06; n=8).Conclusion This trial did not achieve the target sample size therefore was underpowered to demonstrate efficacy of cannabis in slowing ALS progression. However, exploratory analyses generated hypotheses regarding possible effects on pain and cognition which require confirmation in adequately powered studies.Trial registration number (ID: NCT03690791) on 27 September 2018.
Background Migraine affects approximately 14% of the English adult population, generating substantial workload across the National Health Service. Limited neurology capacity necessitates understanding referral patterns from primary care to optimise management pathways.Aim To examine referral rates from primary care in patients with headache in England.Design and setting Retrospective cohort study using Clinical Practice Research Datalink Aurum data from 1569 English practices (September 2012–May 2023).Method Patients aged ≥18 years with headache diagnosis (n=1 058 616 headache excluding migraine; n=476 191 migraine) were followed for 12 months. Referral rates (95% CI) to secondary care were calculated per 100 person-years (/100 PY).Results In headache patients excluding migraine, referrals were highest to ear, nose and throat specialists (11.76 (95% CI 11.65 to 11.86)/100 PY), followed by neurology (5.04 (95% CI 5.00 to 5.09)/100 PY). In migraine patients, referrals were highest to general practitioners (GPs) with extended role in headache (8.63 (95% CI 8.50 to 8.76)/100 PY) and neurology (6.36 (95% CI 6.28 to 6.43)/100 PY).Conclusions Distinct referral patterns were observed between headache excluding migraine patients and migraine patients. High ear, nose and throat referrals for headache may reflect over-exploration of secondary causes and under-recognition of vestibular or cranial autonomic symptoms. Enhanced GP education on migraine diagnosis and equitable primary care access to migraine-specific medication could optimise referral pathways and reduce secondary care demand.